Lexicon Pharmaceuticals (LXRX) Equity Average (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Equity Average data on file, last reported at $155.2 million in Q1 2026.

• Quarterly Equity Average rose 15.4% year-over-year to $155.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.2 million (up 15.4% YoY) and the FY2025 annual result came in at $126.7 million, up 6.04% from the prior year.
• Equity Average rose to $155.2 million in Q1 2026 per LXRX's latest filing, from $113.8 million in the prior quarter.
• Across five years, Equity Average topped out at $264.4 million in Q2 2024 and bottomed at $81.8 million in Q2 2022.
• The 5-year median for Equity Average is $130.6 million (2022), against an average of $142.6 million.
• The widest annual swing landed in 2024, when Equity Average jumped 92.72%; it then sank 52.26% in 2025.
• Tracing LXRX's Equity Average over 5 years: stood at $130.6 million in 2022, then slipped by 10.92% to $116.3 million in 2023, then surged by 39.48% to $162.2 million in 2024, then fell by 29.82% to $113.8 million in 2025, then jumped by 36.32% to $155.2 million in 2026.
• Per Business Quant, the three latest LXRX Equity Average figures stand at $155.2 million (Q1 2026), $113.8 million (Q4 2025), and $124.8 million (Q3 2025).

Peer Comparison